The company’s proprietary INVYMAB platform approach combines viral surveillance and predictive modeling with advanced antibody engineering to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats.

In March 2024, Invivyd received emergency use authorization (EUA) from the US FDA for its first mAb in a planned series of innovative antibody candidates.